News

2017

company

year

domain

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

Moderna 08.12.2017

Industry Veteran Juan Andres Joins Moderna as Senior Vice President of Late Stage Technical Development and Manufacturing

Moderna 08.03.2017

Moncef M. Slaoui, Ph.D. Joins Moderna’s Board of Directors

Moderna 07.27.2017

Moderna Provides Update on mRNA Rare Disease R&D Strategy

Moderna 07.27.2017

Publication in Cell Demonstrates Moderna’s Zika mRNA Vaccine Prevents In Utero Transmission of Zika Virus in Mice, Protects Against Zika-Related Congenital Damage

Moderna 07.13.2017

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease

Moderna 07.13.2017

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

Moderna 06.07.2017

N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density

Moderna 06.02.2017

Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity

Moderna 04.27.2017

Modified mRNA Vaccines Protect against Zika Virus Infection

Moderna 03.09.2017

Loading